Bruna Pellini: RAS–RAF interactions as a potential predictive biomarker for NSCLC
Bruna Pellini, Assistant Professor at the University of South Florida shared a post on X about recent paper by Ryoji Kato et al., titled “In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C-mutant non–small cell lung cancer” published on AACR Journals.
Authors: Ryoji Kato, Hitendra S. Solanki, Hilal Ozakinci, Bina Desai, Harika Gundlapalli, Yu Chi Yang, Ida Aronchik, Mallika Singh, Joseph Johnson, Andriy Marusyk, Theresa A. Boyle, Eric B. Haura
“NEW PUB from the Haura Lab led by the Ryoji Kato on KRAS mutant NSCLC.
This study highlights the importance of evaluating in situ RAS–RAF interactions, using PLA, as a potential predictive biomarker for identifying NSCLC patients most likely to benefit from KRASG12C inhibitors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023